NCT03957122

Brief Summary

In the first visit a magnetic resonance imaging measurement will be done for the use of a neuronavigation System with the aim to control for stable coil position over the course of the trial. EEG positions CP5/CP6 will be used for positioning the coil. Two test sessions will examine the temporary reductions in tinnitus loudness after 1Hz, 10Hz, 20Hz and 0.1Hz rTMS as control condition over left and right temporo-parietal junction accompanied by electroencephalography. For the two-week treatment three arms will be evaluated: standard treatment (1Hz left-sided) in the groups with and without temporary reductions in test sessions and the best protocol as elicited in test sessions.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
22

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2019

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

May 16, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 21, 2019

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2019

Completed
Last Updated

December 19, 2019

Status Verified

December 1, 2019

Enrollment Period

7 months

First QC Date

May 16, 2019

Last Update Submit

December 17, 2019

Conditions

Keywords

tinnitustranscranial magnetic stimulation

Outcome Measures

Primary Outcomes (1)

  • TFI

    Tinnitus Functional Index

    2 weeks

Secondary Outcomes (7)

  • TFI

    12 weeks

  • Mini-TQ

    12 weeks

  • THI

    12 weeks

  • Tinnitus Severity

    12 weeks

  • MDI

    12 weeks

  • +2 more secondary outcomes

Study Arms (3)

individualized rTMS

EXPERIMENTAL

Treatment with the best (highest reduction in tinnitus loudness, most reliable, superior to control condition, most tolerable) protocol as obtained in the test sessions (left vs. right temporoparietal junction, 1Hz, 10Hz, 20Hz, 0.1Hz as active control condition).

Device: repetitive transcranial magnetic stimulation

standard rTMS in responders

ACTIVE COMPARATOR

Treatment with standard protocol: left-sided 1Hz in the group of patients who showed temporary reductions in tinnitus loudness in test sessions.

Device: repetitive transcranial magnetic stimulation

standard rTMS in non-responders

ACTIVE COMPARATOR

Treatment with standard protocol: left-sided 1Hz in the group of patients who did not show temporary reductions in tinnitus loudness in test sessions.

Device: repetitive transcranial magnetic stimulation

Interventions

Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation * 2000 pulses * intensity of 110% resting motor threshold * 10 sessions (daily from Monday to Friday) * positioning of coil according to EEG position CP5/CP6

individualized rTMSstandard rTMS in non-respondersstandard rTMS in responders

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • chronic tinnitus (\> 6 months)
  • at least moderate tinnitus distress
  • no or consistent medication
  • no or consistent Treatments
  • residence in Germany and German speaking

You may not qualify if:

  • objective tinnitus
  • serious and not stable illness (e.g. acute psychosis, severe depression or substance dependence, epilepsy, brain tumor)
  • meeting the contraindications for transcranial magnetic stimulation or magnetic resonance imaging (electric devices or metal implants in the body, e.g. cardiac pace maker, insulin pump)
  • neurological disorders (e.g. cerebrovascular events, neurodegenerative disorder, epilepsy, brain malformation, severe head trauma)
  • addictive disorder with consumption in the last two years
  • regular intake of benzodiazepines
  • participation in another study parallel to the trial
  • pregnancy or breastfeeding period
  • psychiatric confinement

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Psychiatry and Psychotherapy, University of Regensburg

Regensburg, 93053, Germany

Location

MeSH Terms

Conditions

Tinnitus

Interventions

Transcranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

Hearing DisordersEar DiseasesOtorhinolaryngologic DiseasesSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Study Officials

  • Berthold Langguth

    University of Regensburg

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Center II and out-patient clinic of the Department of Psychiatry and Psychotherapy

Study Record Dates

First Submitted

May 16, 2019

First Posted

May 21, 2019

Study Start

May 1, 2019

Primary Completion

November 30, 2019

Study Completion

November 30, 2019

Last Updated

December 19, 2019

Record last verified: 2019-12

Data Sharing

IPD Sharing
Will not share

Locations